Boston Trust Walden Corp Has $63.89 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Boston Trust Walden Corp decreased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.3% in the 2nd quarter, Holdings Channel.com reports. The firm owned 800,166 shares of the company’s stock after selling 19,116 shares during the period. Boston Trust Walden Corp’s holdings in Prestige Consumer Healthcare were worth $63,893,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of PBH. GAMMA Investing LLC raised its stake in Prestige Consumer Healthcare by 35.9% in the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company’s stock worth $162,000 after purchasing an additional 496 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare in the 1st quarter worth about $38,000. QRG Capital Management Inc. raised its stake in Prestige Consumer Healthcare by 8.6% in the 1st quarter. QRG Capital Management Inc. now owns 5,971 shares of the company’s stock worth $513,000 after purchasing an additional 475 shares in the last quarter. Avior Wealth Management LLC raised its stake in Prestige Consumer Healthcare by 38.2% in the 1st quarter. Avior Wealth Management LLC now owns 11,824 shares of the company’s stock worth $1,017,000 after purchasing an additional 3,270 shares in the last quarter. Finally, Advisor Resource Council acquired a new stake in Prestige Consumer Healthcare in the 1st quarter worth about $2,232,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on PBH shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Sidoti upgraded shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price for the company in a research report on Wednesday, September 24th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Finally, Canaccord Genuity Group dropped their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $94.80.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $61.83 on Tuesday. The company has a 50 day simple moving average of $65.02 and a 200 day simple moving average of $75.91. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of 14.51, a P/E/G ratio of 1.93 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a 1 year low of $60.15 and a 1 year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The company had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.Prestige Consumer Healthcare’s revenue for the quarter was down 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.